ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)

医学 阿替唑单抗 膀胱癌 肿瘤科 芽孢杆菌(形态) 内科学 泌尿科 卡介苗 临床试验 外科 临床研究阶段 随机对照试验 膀胱 膀胱肿瘤 不利影响 癌症
作者
Morgan Rouprêt A,Aurélie Bertaut,G. Pignot,Y. Neuzillet,Nadine Houédé,Romain Mathiéu,Luc Corbel,D. Besson,Thomas Seisen,Loïc Jaffrelot,Cedric Michel Lebacle,Stéphane Champiat,Souhil Lebdai,Marc‐Olivier Timsit,Constance Thibault,Lieven Goeman,Á. Juárez Soto,C. La,C. Léger,Yohann Loriot
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:37 (1): 44-52 被引量:67
标识
DOI:10.1016/j.annonc.2025.09.017
摘要

BACKGROUND: Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maintenance regimens); however, BCG therapy still fails in 30%-40% of patients. Prior studies suggest that programmed death-ligand 1 (PD-L1) expression and alterations in immune infiltration might be associated with BCG failure. PATIENTS AND METHODS: The ALBAN trial is an international, 1 : 1 randomized, open-label phase III trial comparing the combination of atezolizumab (an anti-PD-L1 antibody) and BCG (arm B) versus BCG alone (arm A) for BCG-naive patients with high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS). Key secondary endpoints included high-grade recurrence-free survival, complete response rate, and duration of response in patients with carcinoma in situ disease, as well as overall survival. RESULTS: In total, 255 patients were randomly assigned to arm A and 262 to arm B. The trial did not meet its primary endpoint; there was no significant difference in EFS between arms, with a hazard ratio of 0.98 (95% confidence interval 0.71-1.36, P = 0.9106). EFS results were consistent across all prespecified subgroups. The safety profile of the treatment combination was consistent with that of the individual agents but showed higher rates of treatment-related adverse events (TRAEs) and grade ≥3 TRAEs than BCG alone. CONCLUSION: This phase III trial in BCG-naive patients with high-risk NMIBC did not demonstrate an EFS benefit from the addition of atezolizumab to 1-year BCG therapy, in contrast to positive EFS results reported with another PD-(L)1 agent, suggesting that any benefit from checkpoint-BCG therapy may be context- and agent-specific rather than a class effect. Future research should focus on biomarker-driven patient selection and optimization of the timing, duration, and route of checkpoint delivery relative to BCG.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
端庄洋葱发布了新的文献求助10
刚刚
吕津阳完成签到 ,获得积分10
刚刚
1秒前
茶色发布了新的文献求助10
1秒前
小帅发布了新的文献求助10
2秒前
djfndnn完成签到 ,获得积分10
2秒前
cheng发布了新的文献求助30
2秒前
谨慎初曼完成签到,获得积分10
2秒前
酷波er的应助被李思羽采纳,获得30
2秒前
在水一方的应助被碧蓝的若风采纳,获得10
2秒前
HX发布了新的文献求助50
3秒前
3秒前
wangly完成签到,获得积分10
3秒前
开放依琴发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
丘比特的应助被火山采纳,获得30
4秒前
小林不熬夜完成签到,获得积分10
4秒前
4秒前
大山完成签到,获得积分10
4秒前
小马同学完成签到,获得积分20
4秒前
zhanghao发布了新的文献求助10
5秒前
5秒前
livian完成签到,获得积分10
5秒前
5秒前
6秒前
香蕉觅云的应助被Loststar采纳,获得10
6秒前
SCIGGG完成签到,获得积分10
6秒前
6秒前
cheng完成签到,获得积分10
6秒前
6秒前
热爱科研的小孩完成签到,获得积分10
6秒前
123完成签到 ,获得积分10
7秒前
7秒前
奋斗大山完成签到,获得积分10
7秒前
鸭蛋发布了新的文献求助100
7秒前
7秒前
Cao发布了新的文献求助10
8秒前
伞与鞋发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174058
求助须知:如何正确求助?哪些是违规求助? 9566129
关于积分的说明 21784894
捐赠科研通 7768250
什么是DOI,文献DOI怎么找? 3431686
关于科研通互助平台的介绍 2555907
邀请新用户注册赠送积分活动 2476936